Detalles de la búsqueda
1.
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Int J Cancer
; 154(5): 863-872, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37840339
2.
Role of beta-(1â3)(1â6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures.
BMC Cancer
; 24(1): 339, 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38486205
3.
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Eur Radiol
; 33(2): 1174-1184, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35976398
4.
Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer.
Int J Mol Sci
; 24(10)2023 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37240385
5.
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Int J Cancer
; 150(1): 112-123, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34431518
6.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35637412
7.
FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
BMC Cancer
; 22(1): 359, 2022 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35366831
8.
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Int J Cancer
; 149(11): 1935-1943, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310714
9.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Br J Cancer
; 124(3): 587-594, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33154570
10.
Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Oncologist
; 26(12): e2110-e2114, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34431576
11.
Partition: a surjective mapping approach for dimensionality reduction.
Bioinformatics
; 36(3): 676-681, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31504178
12.
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306.
Ann Surg Oncol
; 27(7): 2389-2401, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32172334
13.
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Anticancer Drugs
; 31(8): 856-865, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32639280
14.
[Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer - Interdisciplinary recommendations]. / Stellenwert und qualitative Voraussetzungen der Magnetresonanztomografie für die Therapieplanung beim lokal fortgeschrittenen Rektumkarzinom Interdisziplinäre Empfehlungen.
Z Gastroenterol
; 58(6): 577-582, 2020 Jun.
Artículo
en Alemán
| MEDLINE | ID: mdl-32544967
15.
Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies.
Lancet Oncol
; 20(5): e274-e283, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31044725
16.
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Int J Cancer
; 145(8): 2082-2090, 2019 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30856283
17.
Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial.
Blood
; 139(10): 1593-1597, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34932794
18.
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Int J Cancer
; 142(5): 1047-1055, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29047142
19.
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.
Pharmacogenomics J
; 18(5): 623-632, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29925895
20.
CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.
Eur Radiol
; 28(12): 5284-5292, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29882070